Download
Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non tuberculous mycobacterial isolates.pdf 1,21MB
WeightNameValue
1000 Titel
  • Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract
1000 Autor/in
  1. He, Guiqing |
  2. Wu, Lianpeng |
  3. Zheng, Qingyong |
  4. Jiang, Xiangao |
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2022-09-18
1000 Erschienen in
1000 Quellenangabe
  • 54(1):2500-2510
1000 Copyrightjahr
  • 2022
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1080/07853890.2022.2121984 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518250/ |
1000 Ergänzendes Material
  • https://www.tandfonline.com/doi/figure/10.1080/07853890.2022.2121984?scroll=top&needAccess=true |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • OBJECTIVE: To determine the minimum inhibitory concentration (MIC) distribution of antibacterial drugs and the susceptibility of non-tuberculous mycobacterial (NTM) isolates to provide a reference basis for the clinical selection of an effective starting regimen. METHODS: The common clinical isolates of NTM in the respiratory tract, which met the standards of the American Thoracic Society for NTM lung disease, were collected. The MICs of 81 isolates were determined using the microbroth dilution method (Thermo Fisher Scientific, USA), as recommended by the Clinical and Laboratory Standards Institute, USA. RESULTS: Included were 43 Mycobacterium avium complex (MAC) strains, 24 M. abscessus complex (MAB) strains, and 14 M. kansasii strains. The sensitivity rates of MAC to clarithromycin and amikacin were 81.4% and 79.1%, respectively, while the sensitivity rates to linezolid and moxifloxacin were only 20.9% and 9.3%; the MIC of rifabutin was the lowest (MIC50% was just 2 mu g/mL). After incubation for 3-5 days, the sensitivity rate of MAB to clarithromycin was 87.5%; this decreased to 50% after 14 days' incubation. Most of them were susceptible to amikacin (91.6%), and most were resistant to moxifloxacin (95.8%), ciprofloxacin (95.8%), imipenem (95.8%), amoxicillin/clavulanate (95.8%), tobramycin (79.1%), doxycycline (95.8%) and trimethoprim/sulfamethoxazole (95.8%). intermediate (83.3%) and resistant (16.7%) to cefoxitin. The susceptibility to linezolid was only 33.3%. The sensitivity and resistance breakpoints of tigecycline were set to <= 0.5 and >= 8 mu g/mL, respectively, and the sensitivity and resistance rates were 50% and 0%, respectively. M. kansasii was susceptible to clarithromycin, amikacin, linezolid, moxifloxacin, rifampicin and rifabutin (100%). DISCUSSION: In Wenzhou, clarithromycin, amikacin and rifabutin have good antibacterial activity against MAC, while linezolid and moxifloxacin have high resistance. Amikacin and tigecycline have strong antibacterial activity against MAB, while most other antibacterial drugs are resistant to varying degrees. Most antibacterial drugs are susceptible to M. kansasii and have good antibacterial activity. Conclusion: The identification of NTM species and the detection of their MICs have certain guiding values for the treatment of NTM lung disease. KEY MESSAGE: The three most common respiratory non-tuberculous mycobacterial (NTM) isolates with clinical significance in the Wenzhou area were tested for drug susceptibility. The broth microdilution method was used to determine the minimum inhibitory concentration distribution of antibacterial drugs and the susceptibility of NTM isolates to provide a reference basis for the clinical selection of an effective starting regimen.
1000 Sacherschließung
lokal Drug susceptibility
lokal Mycobacterium abscessus complex (MAB)
lokal Mycobacterium avium complex (MAC)
lokal Non-tuberculos mycobacteria (NTM)
lokal Mycobacterium kansaii (M. kansaii)
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SGUsIEd1aXFpbmc=|https://frl.publisso.de/adhoc/uri/V3UsIExpYW5wZW5n|https://frl.publisso.de/adhoc/uri/WmhlbmcsIFFpbmd5b25n|https://frl.publisso.de/adhoc/uri/SmlhbmcsIFhpYW5nYW8=
1000 Label
1000 Förderer
  1. Science and Technology Plan Project of Wenzhou, China |
  2. Basic Public Welfare Research Program of Zhejiang Province |
1000 Fördernummer
  1. Y20180192
  2. LGF20H010003
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Science and Technology Plan Project of Wenzhou, China |
    1000 Förderprogramm -
    1000 Fördernummer Y20180192
  2. 1000 joinedFunding-child
    1000 Förderer Basic Public Welfare Research Program of Zhejiang Province |
    1000 Förderprogramm -
    1000 Fördernummer LGF20H010003
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6435557.rdf
1000 Erstellt am 2022-10-17T15:26:29.454+0200
1000 Erstellt von 329
1000 beschreibt frl:6435557
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet 2022-12-22T10:52:42.624+0100
1000 Objekt bearb. Fri Nov 11 12:48:10 CET 2022
1000 Vgl. frl:6435557
1000 Oai Id
  1. oai:frl.publisso.de:frl:6435557 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source